AEterna Zentaris Inc. das wird - 500 Beiträge pro Seite

[paula5]

spannend

[paula5]

Weekly Stock Watch, Week Of 28 January 2013

AEterna Could Move On Results Release

AEterna Zentaris (AEZS) is one to watch again with an interim milestone due within the current quarter in regards an ongoing Phase III trial for Perifisone in the treatment of multiple myeloma (MM). The milestone entails an interim trial review from an independent Data Safety Monitoring Board, which - upon completion of the review - will then make a recommendation on whether or not the trial should continue. Such events often provide investors with a clear sign of validation, or not, of the effectiveness of the trial. It should also be noted, however, that these reviews may be more keen on safety and not necessarily efficacy. For instance, Oncothyreon's (ONTY) Stimuvax trials were recommended to move forward last spring, too, by an independent board, but the trial ended up not meeting its endpoints. So while a recommendation for continuation is a positive event, it's not a definitive sign of success.

That said, it's not unusual to see shares of a company expecting interim or actual trial results to run leading into the catalyst event - as demonstrated by the twenty percent-plus run by Keryx Biopharmaceuticals (KERX) this month - and its possible that AEZS could follow suit. AEterna's sixty five million dollar market cap indicates only modest expectations by investors at this point, but that could change quickly if anticipation builds to the likelihood of an imminent results release and catalyst traders also jump on board. Already, popular investing sites have started tipping AEZS as stock to watch based on the pending catalyst and pipeline potential and new interest could be drawn in as a result.

Considering that the AEterna pipeline only starts with Perfisone - and by no means finishes with it - this could be one to keep an eye on for longer term potential, regardless of the outcome of the upcoming trial results. AEZS-130, for example, is being prepared for an NDA filing with the FDA during the current quarter as a diagnostic test for Adult Growth Hormone Deficiency. AEterna maintains world-wide rights to the product, which has also received an orphan drug designation from the FDA. This milestone event could also provide a modest catalyst to the share price over the short term.

Another anti-cancer compound, AEZS-108, is slated to return interim Phase II results in the treatment of endometrial cancer this quarter, another event that could provide a share price catalyst. This product has already proven successful in multiple Phase II trials and is also being prepared for a near-term launch of a Phase III trial in the endometrial cancer indication.

The current market cap does not give much enthusiasm to the MM indication, in my opinion, meaning that any positive results could lead to a swift move higher. More accurately, the cap is valued for the still-developmental stage of the rest of the pipeline, keeping AEZS on the radar as a decent speculative play moving forward with the potential to return volatile gains as the catalysts unfold.

Right now, attention is on the MM trial results. Shares could be positioned for a pre-results run, but investors should keep in mind that such runs are speculative and do not indicate success or failure, so it may be a wise move to bank some profits with trading shares while potentially holding onto a core group of long shares to play future catalysts, if investors choose to follow the story. Numerous analysts have also jumped on board recently and either initiated or upgraded coverage of the company, another potentially strong sign moving forward. Nice one to watch, with multiple milestone events pending within the quarter.

[paula5]

kommt heut der Angriff auf die 2,80$ ?

[paula5]

AEterna Zentaris Inc. Pre-Market Trading
AEZS
$2.76
*
0.01

0.36% Get AEZS Alerts


Read more: http://www.nasdaq.com/symbol/aezs/premarket#ixzz2JN0QZX40

[paula5]

http://www.aezsinc.com/pdfdyn/Fact_sheet_eng.pdf

[paula5]

http://www.aezsinc.com/pdfdyn/Presentation-Jan%202013.pdf

[paula5]

na baut sie genug Dampf auf heut?

[paula5]

mit volldampf durch AEterna Zentaris Inc. Real Time Stock Quotes
AEZS $2.85* 0.1 3.63%

[paula5]

[paula5]

jetzt aber 2,90$

[paula5]

fett 3 $$ keine halben sachen was

[paula5]

Healthcare, Biotech, Pharmaceutical:

Clarification On Upcoming AEterna Zentaris Catalysts

In the weekly write up published Monday, we discussed the potential for shares of AEterna Zentaris (AEZS) to start moving based on the pipeline potential and upcoming catalysts. In regards to the upcoming Phase III trial milestone for Perifisone in the treatment of multiple myeloma (MM) within the current quarter, it should be more accurately noted - as outlined in a "Fact Sheet" published on the company website - that this will be an interim analysis of the data by an independent monitoring committee which, upon review, will recommend (or not) that the trial be continued. Such events often provide investors with a clear sign of validation, or not, of the effectiveness of the trial. It should also be noted, however, that these reviews may be more keen on safety and not necessarily efficacy. For instance, Oncothyreon's (ONTY) Stimuvax trials were recommended to move forward last spring, too, by an independent board, but the trial ended up not meeting its endpoints. So while a recommendation for continuation is a positive event, it's not a definitive sign of success.

Although some skepticism remains surrounding Perifisone in the eyes of investors following the early-2012 trial failure, analyst optimism has been higher in regards to the potential for success in the MM trial and an interim look by the independent committee could reaffirm that fact.

AEZS shares moved higher by six percent on Monday and could continue that trend as the Perifisone and other catalyst continue to play out over the duration of the quarter. Keryx Biopharmaceuticals (KERX) showed us on Monday just how quickly the tide can turn for a once-beaten down stock in this sector.

[paula5]

3,30$ die machen keine halben sachen die amis

[Fruehrentner]

..

[Gustl24]

Antwort auf Beitrag Nr.: 44.077.812 von paula5 am 29.01.13 16:26:43

nice call - gratulation